Subcutaneous immunoglobulin has been tested in small studies in MMN14, 15, 16, 17; although maintenance was not obtained in all subjects, this option could be more convenient for some patients, as for chronic inflammatory demyelinating polyneuropathy.18 The addition of eculizumab, which neutralises human complement C5, to IVIg in one small‐controlled trial showed a trend towards improvement19 which needs to be confirmed in larger studies. The gene discussed is C5; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.